GlassScriptPhysician profile
Paden C Hendrickson
NPI 1154434637
$2,399.04
in general payments reported to CMS, 2019-2025
12 companies · $44.19 in 2025
The $44.19 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $316 · 2020: $397 · 2021: $421 · 2022: $577 · 2023: $545 · 2024: $98.81 · 2025: $44.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $688.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $688.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $600.64 | 2019-2024 | Xarelto |
| Amgen INC. | $587.47 | 2020-2024 | Tavneos, Repatha |
| Astrazeneca Pharmaceuticals LP | $301.46 | 2019-2022 | |
| Boston Scientific Corporation | $237.67 | 2020-2025 | General - Therapies, Watchman Access System |
| Biotronik INC. | $147.66 | 2022 | |
| Abbott Laboratories | $145.49 | 2023 | Mitraclip |
| Edwards Lifesciences Corporation | $130.94 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Vifor Pharma, INC. | $124.84 | 2019 | |
| Allergan, INC. | $49.92 | 2020-2021 | |
| Pfizer INC. | $28.92 | 2023 | |
| Abbvie INC. | $23.57 | 2021 | |
| Novartis Pharmaceuticals Corporation | $20.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paden Hendrickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.